Navigation Links
Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
Date:1/5/2012

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.  PF-05280602 has been engineered to provide improved acute and prophylactic treatment for hemophilia A & B patients with inhibitors.  The IND filing and initiation of the Phase 1 clinical trial triggered additional milestone payments of $7.0 million payable to Catalyst by Pfizer under the terms of their research and license agreement. 

"We are very excited to see the lead candidate from Catalyst's hemostasis franchise advance into human clinical trials," said Nassim Usman, Ph.D., Catalyst's CEO.  "In parallel, Catalyst is independently achieving significant progress in engineering next-generation recombinant human Factor IX and Xa variants with highly differentiated advantages for the treatment of acute and prophylactic bleeding disorders, including hemophilia and non-hemophilia indications.  We are diligently executing on our goal of expanding Catalyst's high-value pipeline of novel engineered proteases." 

In June 2009 Catalyst and Wyeth LLC, now a wholly owned subsidiary of Pfizer Inc., formed an exclusive, worldwide collaboration for the discovery, development and commercialization of improved, second-generation Factor VIIa products.  Total payments under the collaboration, including an upfront payment of $21 million, ongoing research funding and milestone payments, could exceed $500 million, exclusive of double-digit royalty payments. 

About Catalyst Biosciences 

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that ta
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)...  ErgoNurse, the leader in bedside safety management solutions, and ... the United States , have formalized a partnership ... skilled nursing markets. ... Thousands of healthcare professionals in ... of the ErgoNurse products to stop unnecessarily utilizing their backs ...
(Date:6/2/2015)... announced today they are expanding their reach nationally by providing customers with on-site 17025 accredited pipette calibrations. ... ... ... ... Photo - http://photos.prnewswire.com/prnh/20150601/219758 ...
(Date:6/2/2015)... Today AmerisourceBergen, a global healthcare solutions leader, ... Olive Branch, MS ; ... . The facilities will operate within AmerisourceBergen,s existing ... increase supply chain efficiency and enhance patient care. ... ongoing investments, more than $1 billion over the last ...
Breaking Medicine Technology:ErgoNurse and Briggs Healthcare Positioned to Completely Eliminate the Unnecessary Cost of Healthcare-Related Back Injuries 2Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 2Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 3Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 4AmerisourceBergen to Build Three New Distribution Centers 2
... 1 Merriman Curhan Ford Group, Inc. (Nasdaq: ... Therapeutics, Inc. in the recent merger with Raptor Pharmaceuticals ... company is named "Raptor Pharmaceutical Corp." and commenced trading ... under the ticker symbol "RPTP." , Further details on ...
... 1 Ocular Therapeutix, Inc. announced today the expansion ... Mr. Daniel Myers and Mr. Bernard Haffey. , Mr. ... Alimera Sciences, Inc., a biopharmaceutical company that is developing ... Alimera has raised venture funding totaling approximately $90M. ...
Cached Medicine Technology:Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp. 2Ocular Therapeutix, Inc. Appoints Two New Board Members 2
(Date:6/2/2015)... (PRWEB) June 02, 2015 April 8th, ... music venue into Durkin Entertainment’s “RockNRolla Movie Awards” EcoLuxe ... Bend, that gathered some of the world’s top providers ... The event was organized by Debbie Durkin, Los Angeles’ ... film, the EcoLuxe Lounge is a premier red carpet ...
(Date:6/2/2015)... On Wednesday, May 27, 2015, professional driver, Brian Smith, drove ... 207.9 mph. In the process, Hennessey’s potent pony car ... mark. Jay Leno was on hand to witness the ... Garage, which will air on CNBC later this year. , ... oval at the Continental Tire Proving Grounds located in Uvalde, ...
(Date:6/2/2015)... Orlando, FL (PRWEB) June 02, 2015 ... can enjoy quality care in a more convenient location ... Publix in Partin Village Plaza, 2310 E. Irlo Bronson ... location is located less than a mile away from ... with warm décor, more spacious patient areas with digital ...
(Date:6/2/2015)... June 02, 2015 The 3TVPhoenix contest, conducted ... watch the station’s 6:00 a.m. Good Morning Arizona program for ... the station’s Facebook page. , Lisa Allen of ... She plans to apply the monthly $1,000 prize to ... a stay-at-home mom, expressed her surprise and gratitude at winning, ...
(Date:6/2/2015)... The term “Augmented Reality” was coined ... on the real world. Since then many promising technologies ... a map of the vasculature on the surface of ... , AccuVein, the leader in vein visualization, exemplifies this ... and such widespread adoption of its AccuVein AV400 devices ...
Breaking Medicine News(10 mins):Health News:Choices Recovery South Bend Discusses Addiction With Rising Hollywood Star Ben Stillwell 2Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:Coast Dental Office Opening In Kissimmee with Expanded Technology 2Health News:Scottsdale Resident Named $12,000 Prize Winner- Arizona Central and KTVK 3TV Phoenix Partner in Mortgage Giveaway Contest 2Health News:Vein Visualization Emerges as Premier Augmented Reality Application 2
... March 15 Quantros, a leading healthcare software and services provider of data management, decision support analytics, and clinical business intelligence solutions today ... ... , ... ...
... ... that builds open source platforms and develops advanced research solutions, has ... totaling more than $600,000 to focus research efforts on developing approach-specific, ... is to work towards an interactive simulator that replicates future neurosurgery ...
... traditional screening tests for potential anti-cancer drugs, scientists ... technique that more closely simulates the real-world conditions ... normal cells. Because these neighboring cells key ... microenvironment" can alter the effectiveness of anti-cancer ...
... take the place of a good clinical exam, study finds ... symptoms, but 70 percent of able-bodied professional and collegiate hockey ... MRIs. , "This study was done to see if abnormal ... Dr. Matthew Silvis, an assistant professor in the department of ...
... levels below currently recommended levels did not ... cardiovascular disease events in adults with type 2 diabetes ... events, according to new results from the landmark Action ... Similarly, treating multiple blood lipids with combination drug therapy ...
... MARCH 13, 2010 The announcement of a new ... Artery Bypass Surgery for Effectiveness of Left Main Revascularization), ... graft surgery in patients with left main coronary artery ... Paradigms," a symposium presented by the Cardiovascular Research Foundation. ...
Cached Medicine News:Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 2Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 3Health News:Quantros Announces Support for Oracle's Enterprise Healthcare Analytics (EHA) Solution to Improve the Quality and Safety of Patient Care 4Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 2Health News:National Institutes of Health Awards Kitware Over $600,000 to Develop Advancements in Neurosurgical Simulation 3Health News:New cancer drug screening technique more closely mirrors reality 2Health News:New cancer drug screening technique more closely mirrors reality 3Health News:Scans May Be Misleading for Hockey Players 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6Health News:EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery 2
... marketing software enables the efficient capture of ... also has many built-in time saving and ... of name fields and numerous user definable ... data input. The pre-defined options in the ...
... Management software- RLISYS provides ... Software, Support, and Training ... Optometry, Ophthalmology, and Opticianry- ... operations, allowing you to ...
The K-4500 automated hematology analyzer offers fast reliable test results of 18-parameter plus 3-histograms, valuable for effective diagnosis....
The SF-3000 automated hematology analyzer can provide accurate and precise 23-parameter hematolgy results including a fully automated WBC 5-part differential from a compact space-save design....
Medicine Products: